2865 Outcome of systemic treatments after first line platinum and cetuximab treatment in patients with recurrent/metastatic (RM) head and neck squamous cell cancer (HNSCC): A retrospective analysis

Published on Sep 1, 2015in European Journal of Cancer7.275
· DOI :10.1016/S0959-8049(16)31603-3
Marco Siano12
Estimated H-index: 12
 , Carlo Resteghini13
Estimated H-index: 13
 + 8 AuthorsPaolo Bossi37
Estimated H-index: 37
Sources
Abstract
References0
Newest
Cited By2
Newest
Jul 1, 2019·European Journal of Cancer7.28
#1Roberta DepenniH-Index: 3
#2Maria Cossu Rocca (IEO: European Institute of Oncology)H-Index: 13
Last. Paolo BossiH-Index: 37
view all 12 authors...
Abstract Aim The aims of the study are to evaluate the clinical outcomes of first-line treatment with platinum-based chemotherapy and cetuximab in patients with relapsing/metastatic head and neck cancer (RM HNC) and to identify predictors of treatment response. Methods This is a retrospective, observational, longitudinal, real-world study involving 6 oncology centres in Italy. All consecutive patients with RM HNC treated between January 2007 and December 2016 with a first-line therapy consisting...
5 CitationsSource
May 9, 2017·Frontiers in Oncology4.85
#1Athanassios Argiris (Thomas Jefferson University)H-Index: 55
#2Kevin J. Harrington (ICR: Institute of Cancer Research)H-Index: 95
Last. Lisa Licitra (University of Milan)H-Index: 68
view all 7 authors...
The major development of the past decade in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) was the introduction of cetuximab in combination with platinum plus 5-fluorouracil chemotherapy, followed by maintenance cetuximab (the “EXTREME” regimen). This regimen is supported by a phase 3 randomized trial and subsequent observational studies and it confers well-documented survival benefits, with median survival approximately ranging b...
63 CitationsSource
1